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Abstract Haemorrhagic stroke is a severe stroke subtype
with high rates of morbidity and mortality. Although this
condition has been recognised for a long time, the pro-
gressing haemorrhagic stroke has not received adequate
attention, and it accounts for an even worse clinical out-
come than the nonprogressing types of haemorrhagic
stroke. In this review article, we categorised the progressing
haemorrhagic stroke into acute progressing haemorrhagic
stroke, subacute haemorrhagic stroke, and chronic pro-
gressing haemorrhagic stroke. Haematoma expansion,
intraventricular haemorrhage, perihaematomal oedema, and
inflammation, can all cause an acute progression of haem-
orrhagic stroke. Specific ‘second peak’ of perihaematomal
oedema after intracerebral haemorrhage and ‘tension
haematoma’ are the primary causes of subacute progres-
sion. For the chronic progressing haemorrhagic stroke, the
occult vascular malformations, trauma, or radiologic brain
surgeries can all cause a slowly expanding encapsulated
haematoma. The mechanisms to each type of progressing
haemorrhagic stroke is different, and the management of
these three subtypes differs according to their causes and
mechanisms. Conservative treatments are primarily con-
sidered in the acute progressing haemorrhagic stroke,
whereas surgery is considered in the remaining two types.
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CTA Computed tomography angiography
PET-CT Positron emission tomography-computed
tomography
rFVIIa Recombinant factor VIIa
FFP Fresh frozen plasma
CEICH Chronic encapsulated intracerebral haematoma
Introduction
Haemorrhagic stroke, which accounts for 10–20 % of all of
the new strokes that occur every year [78], has a 1-month
mortality rate of approximately 40 % [164]. Although it
has drawn the attention of researchers because of the high
rates of morbidity and mortality, the outcomes and prog-
nosis of intracranial haemorrhage have not improved sig-
nificantly during the last several decades [142, 164].
Progressing stroke, also known as progressive stroke,
stroke-in-progression, stroke-in-evolution, and deteriorating
stroke, has been a clinical concept for a long time [27, 54].
Progressing stroke happens often within 36–72 h, with marked
deterioration in clinical manifestations measured by the
Scandinavian Stroke Scale or the Canadian Stroke Scale [83,
117, 154]. This concept was traditionally limited to ischaemic
stroke [116], and haemorrhagic stroke was often ruled out in
the initial studies of progressing stroke [84]. However, evi-
dence has shown that a progression also exists in the haem-
orrhagic stroke [27, 54, 113]. Several researchers have shown
that primary haemorrhagic stroke is more often associated with
progression than ischaemic stroke [18] and that early deterio-
ration is associated with a poorer outcome [93].
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Early neurological deterioration of intracerebral haem-
orrhage has been recognised in many patients with haem-
orrhagic stroke [30, 46, 93, 100, 113]. As with progressing
ischemic stroke, a deterioration of clinical signs and
symptoms often happens within 24–72 h with intracerebral
haemorrhage and is associated with haematoma expansion
[30], perihaematomal oedema [46], intraventricular haem-
orrhage [100], and inflammation [155]. The expansion of
haematoma may account for most of the progression [100,
113, 150]. Additionally, in the second to third weeks after
the onset of intracerebral haemorrhage, many patients may
undergo a deterioration of symptoms after the initial alle-
viation by conservative management, which indicates a
subacute progression [171, 182]. Furthermore, the pro-
gression of haemorrhage may appear to be a chronic form,
in which the gradual formation of an encapsulated intra-
cerebral haematoma may cause progressive neurologic
deficits over weeks or months [64, 69, 133]. Therefore, the
concept of progressing haemorrhagic stroke should be
separated from the progressing ischaemic stroke, because
the causes, pathogenesis, mechanisms, manifestations and
management of the former all differ from the latter.
In this review article, we proposed the concept of pro-
gressing haemorrhagic stroke and summarised the three
categories of progressing haemorrhagic stroke, which are
as follows: acute progressing haemorrhagic stroke, suba-
cute progressing haemorrhagic stroke and chronic encap-
sulated intracerebral haematoma. We explored several
aspects of their causes, mechanisms and management.
Acute progressing haemorrhagic stroke
Clinical features
Many researchers have observed an early neurological
deterioration in spontaneous intracerebral haemorrhage.
Despite the difference in the diagnostic criteria of early
neurological deterioration, the studies have all shown a
significant deterioration that occurs in 22.9–37 % of the
patients [46, 100, 113, 150, 155]. In several retrospective
studies, an ICH score of [2, white blood cell count of
[10,000 cells/mL3, an initial Glasgow Coma Scale score of
\14, large haemorrhage volume with significant mass
effect on initial CT scan, haematoma expansion and
intraventricular haemorrhage were shown to be associated
with early neurological deterioration [46, 150, 155]. In a
prospective study of 46 patients, Mayer et al. [113] proved
that larger initial haemorrhages and marked initial mass
effect predicted early neurological deterioration. A pro-
spective study of 266 patients by Leira et al. [100] showed
that on admission to the hospital, body temperature of
37.5 C, increased neutrophil count and serum fibrinogen
levels of [523 mg/dL could all independently predict
neurological deterioration, whereas at 48 h, early ICH
growth, intraventricular bleeding and highest systolic blood
pressure were associated with neurological deterioration.
Patients who experienced early neurological deterioration
demonstrated significantly increased morbidity and mor-
tality rates than those who did not [46, 100, 113]. The
studies that focused on the early neurological deterioration
are listed in Table 1.
Causes
Haematoma expansion
Haematoma expansion refers to the expansion of the
haemorrhagic volume within the first 3–72 h, mostly
within 6 h [50, 87]. Detected by neuroimaging methods,
this expansion occurs in 13–40 % in all of the reported
patients [20, 51, 88]. The definition of haematoma expan-
sion is not universally agreed upon, and the commonly
used definition is an increase in the volume of intraparen-
chymal haemorrhage of [33 % between the baseline and
the repeated CT, increase of volume by C12.5 cm3 or by
C1.4 times [20, 50, 87]. Haematoma expansion not only
accounts for a major part of the acute progression in the
acute phase of intracerebral haemorrhage [46, 100, 113],
but is also independently associated with a poor outcome
[20, 30, 32, 51].
Intraventricular haemorrhage
Intraventricular extension of haemorrhage is another dete-
riorating factor of early ICH [100, 155]. Intraventricular
extension may occur simultaneously with ICH or within
24–72 h after the onset of initial ICH, in 20–55 % of all
ICH patients [106, 152]. Steiner et al. [152] and Bhattathiri
et al. [16] all showed that ICH patients with intraventric-
ular haemorrhage had a worse functional outcome com-
pared to those without intraventricular hemorrhage.
Adjusting for the ICH score and haematoma expansion,
intraventricular haemorrhage is still associated with a
higher mortality rate within the patients’ hospitalisation
stay [106].
Perihaematomal oedema
Perihaematomal oedema volume increases significantly
after onset within the first 24 h after spontaneous ICH [56].
The chronological CT images showed that perihaematomal
oedema increased rapidly within 3 days after onset and
reached its initial peak in the fourth or fifth day [79, 165].
The highly evident initial mass effect could also contribute
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to the initial haemorrhagic stroke progression [46, 113,
182].
Inflammation
Sun et al. [155] reported that a white blood cell above
10,000/mL3 on hospital admission or within the first 72 h
of hospital admission was highly associated with deterio-
ration. Leira et al. [100] also showed that a body temper-
ature of above 37.5 C and increased neutrophil count are
predictors of early neurological deterioration. The inflam-




Continued haemorrhage from the primary haemorrhagic
vessel or secondary bleeding into the periphery of the clot
from the stretching of the surrounding vessels may account
for the initial haematoma expansion or intraventricular
haemorrhage [20, 43]. The ceaseless bleeding or re-
bleeding in ICH may result from coagulopathy in certain
patients. Haematoma expansion is shown to be positively
associated with liver disease [87] and the amount of alco-
hol consumption [50], and negatively associated with the
level of fibrinogen [50]. Warfarin use was associated with
both haematoma expansion and intraventricular haemor-
rhage [17, 45, 47]. Broderick et al. and Yildiz et al. found a
correlation between antiplatelet therapy and haematoma
expansion [19, 180]. The low serum LDL cholesterol level
was also reported to be associated with a higher haema-
toma expansion rate; researchers think that this association
is related to the function of LDL to maintain vascular
integrity [144].
Hypertension
Kazui et al. [87] showed that an interaction of hyper-
glycaemia and hypertension on hospital admission was
associated with haematoma expansion. Takeda et al. [159]
showed that blood pressure of [160 mmHg measured at
1.5 h after admission was significantly associated with
haematoma expansion. Steiner et al. [152] also showed that
increased baseline blood pressure was associated with
intraventricular haemorrhage growth. Sykora et al. [156]
showed that decreased baroreflex sensitivity was signifi-
cantly correlated with increased blood pressure fluctuation
and was an independent predictor of relative oedema. The













Prospective 46 15 (33 %) Causes:
Haematoma enlargement, perihaematomal oedema,
infarction;
Predictive factors:
Larger initial haemorrhages, marked mass effect
Flemming
et al. [46]
Retrospective 61 16 (26 %) Predictive factors:
Glasgow Coma Scale score \14, Imaging
characteristics such as haemorrhage volume
[60 mL; shift of the septum pellucidum;
effacement of the contralateral ambient cistern;
widening of the contralateral temporal horn;
Causes:
Haematoma enlargement, perihaematomal oedema
Leira et al.
[100]
Prospective 266 61 (22.9 %) Predictive factors:
On admission: Body temperature of 37.5 C,
neutrophil count, serum fibrinogen levels of
523 mg/dL;
At 48 h: early ICH growth, intraventricular bleeding,




Retrospective 184 19 (10 %) Causes:




Retrospective 83 31 (37 %) Predictive factors:
Midline shift on imaging; ICH score; white blood cell
count [10,000/mL3
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antihypertensive therapies, which have become routine
therapeutic methods in ICH, have received fair results in
reducing haematoma enlargement, which will be described
subsequently [8, 90, 137].
Hyperglycaemia
Hyperglycaemia on admission is an important predisposing
factor for haematoma expansion [19]. Querish et al. [138]
analysed the blood glucose of the ICH patients measured
repeatedly after hospital admission over 3 days, and the
results showed that those with increasing blood glucose had
increased haematoma expansion and perihaematomal
oedema, compared to those with decreasing blood glucose
measurements. A linear correlation of intraventricular
haemorrhage and hospital admission hyperglycaemia has
also been detected by Appelboom et al. [9]. In an experi-
mental model, Liu et al. [104] showed that hyperglycaemia
increased haematoma expansion through the effect of
increased kallikrein, which inhibits platelet aggregation.
Hyperglycaemia may result from a history of diabetes, or
stress reaction of ICH [170]. Many studies have shown that
hyperglycaemia at the time of hospital admission is asso-
ciated with early mortality and poor outcome in ICH
patients [14, 89, 98, 170].
Haemorrhagic location
For patients with lobar ICH, an early mortality was asso-
ciated with the involvement of the inferior parietal lobule,
posterior insula and posterolateral thalamus, whereas for
patients with basal ganglia ICH, early mortality was
associated with a large region extending from the cortex to
the brainstem [97]. Intraventricular haemorrhage extension
is correlated with the primary location of ICH [152]. A
retrospective study by Hallevi et al. [66] showed that tha-
lamic and caudate locations had the highest intraventricular
haemorrhage frequency. Lee et al. [97] also detected a
higher incidence of intraventricular haemorrhage in the
thalamic and basal ganglia. Intraventricular haemorrhage
patients including the third and fourth ventricle or ICH
patients with insular involvement are reported to have
lower baroreflex sensitivity than the patients without these
involvements, suggesting that involvement of these sites
could contribute to impairment of autonomic blood pres-
sure regulation [157, 158]. Hypertensive responses can be
exaggerated and additive because of the impaired barore-
ceptor sensitivity [135].
Vasogenic oedema
Early perihaematomal oedema could be vascular in origin
[22, 23]. Several animal experiments have confirmed that
early oedema formation occurs despite an intact blood–
brain barrier [168]. The oedema occurrence and the volume
in thrombolysis-related patients with ICH are all less fre-
quently observed than those seen in patients with sponta-
neous ICH, indicating that an existence of a clot is
necessary for the presence of hyperacute oedema [55].
Blood clot retraction could force the serum into the peri-
haematomal space to form vasogenic oedema [178].
Butcher et al. [23] investigated 21 patients with ICH using
perfusion-weighted MRI and diffusion-weighted MRI
within 10 h; they found that water diffusion in the peri-
haematomal region was significantly increased and was
independently correlated with perihaematomal oedema
volume, and they suggested that the hyperacute oedema
was, for the most part, plasma-derived.
Cytotoxic factors and inflammation
Thrombin, which is formed in the activated coagulation
cascade in the early phase of ICH, primarily contributes to
the development of early perihaematomal oedema [177] by
activating Src kinase phosphorylation to destroy the blood–
brain barrier via its protease-activated receptors [103].
Several animal studies have shown that thrombin could
induce apoptosis of neurons and astrocytes [38], potentiate
glutamate NMDA receptor function [10, 57], activate
microganglia [119], activate autophagy process [71] or
induce TNF-alpha release [73]. Also, the activated
inflammation cascade may contribute to brain damage.
Heme oxygenase, cellular fibronectin, interleukin-6,
tumour necrosis factor-alpha, matrix metalloproteinase-9
(MMP-9) overexpression are all shown to be associated
with haematoma expansion [48, 86, 149, 169]. Lee et al.
[99] showed that by blocking the MMP-9 modulations in
the experimental ICH of rats, a reduction of haematoma
expansion can be observed (Fig. 1).
Each of the predisposing factors contributes to the
pathogenesis of acute progressing haemorrhagic stroke,
whereas several factors affect each other. The interaction
of all causes promotes the progressing together.
Prediction of acute progressing haemorrhagic stroke
The predisposing factors described all predict the pro-
gression of haemorrhagic stroke. Additionally, researchers
have tried to develop more effective ways to predict the
progressing haemorrhagic stroke. Because haematoma
expansion accounts for the majority of acute progressing,
the major explorations on predictions are on haematoma
expansion. Several radiological methods have been
developed.
Haematoma enlargement is less likely to occur in those
who have a long interval ([6 h) from onset to first CT [12,
2064 J Neurol (2014) 261:2061–2078
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87]. ICH volume on baseline CT was positively associated
with both haematoma expansion and intraventricular
haemorrhage occurrence [66, 129]. A meta-analysis con-
cluded that a smaller initial haematoma is less likely to
expand [39].
Researchers have described the predictive radiological
signs of the initial CT on admission to the hospital. A CT
angiography ‘spot sign’ has proven to be an effective
means for predicting haematoma growth [21, 35, 166]. The
concept of the CTA ‘spot sign’ has evolved from the initial
concept of contrast extravasation on postcontrast CT and
was thought to represent ongoing bleeding [21, 101]. It was
defined to be one or more foci of enhancement within the
haematoma on CTA source images [166]. Four criteria
have been proposed to identify the ‘spot sign’: (1) serpig-
inous or spot-like appearance within the margin of a
parenchymal haematoma without connection to an outside
vessel; (2) a contrast density of[1.5 mm in diameter in at
least one dimension; (3) a contrast density (Hounsfield
units, HU) of at least double that of the background
haematoma; and (4) no hyperdensity at the corresponding
location on non-contrast CT [163].
A multicentre, prospective, observational study has
shown that the ‘spot sign’ significantly predicted haema-
toma expansion with a sensitivity of 51 % and specificity
of 85 %, and was associated with a worse prognosis and
increased mortality [35]. Several researchers have sug-
gested that postcontrast CT extravasation could be an
alternate to add the predictive value and sensitivity of spot
sign [40, 65]. Furthermore, Almandoz et al. have devel-
oped a ‘spot sign score’ system, involving spot sign num-
bers, maximal axial dimension and maximal attenuation.
The higher scores are associated with higher in-hospital
mortality and poor outcome [33, 34]. A clinical trial is
being conducted to test its predicting value in early
haematoma growth [59] (Fig. 2).
However, although ASA/AHA recommended CTA or
contrast CT to identify the patients at risk for haematoma
expansion [122], neither of them is a routinely performed
examination at the time of hospital admission in many
institutions. Haematoma density heterogeneity could be a
substitute for the prediction of haematoma expansion.
Haematoma heterogeneity refers to the irregularity of
shape and density of the initial haematoma on the CT scan,
and researchers have found an association between
haematoma heterogeneity and haematoma expansion [13,
81]. Takeda et al. [159] concluded that the presence of
haematoma volume above 16 mL, haematoma heteroge-
neity and 1.5 h of a systolic blood pressure above
160 mmHg together increased the likelihood of haema-
toma expansion to approximately 59 %. Although its def-
inition was traditionally arbitrary, Ji et al. [81] defined the
haematoma heterogeneity as a difference of over 20 HU in
CT value between two regions exceeding 10 mm2 in area.
Barras et al. used quantitative CT densitometry to measure
mean attenuation, square root of variance, coefficient of
variation, skewness and kurtosis of the attenuation distri-
bution of the haematoma; they found that the coefficient of
Fig. 1 Mechanism of acute
progressing haemorrhagic
stroke
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variation and the square root of variance, along with the
basic haematoma volume, are predictors of greater growth.
They suggested that quantitative CT densitometry can be
used to identify haematoma heterogeneity [12]. Addition-
ally, Ji et al. described a characteristic ‘haematom-
a enlargement border’, which was defined as an obvious
boundary between high- and low-density regions within the
primary haematoma on the CT. The haematoma enlarge-
ment border reflects on-going bleeding and its presence
may be associated with potential haematoma expansion
[81] (Fig. 3).
Managements of acute progressing haemorrhagic stroke
Osmotherapy
Osmotherapy with mannitol is often applied in the acute
phase of ICH to control the increased intracranial pressure.
However, mannitol may have the possibility of aggregating
haematoma expansion or perihaematomal oedema, because
it may open the blood–brain barrier [29, 141] or reverse the
osmotic concentration gradient between the oedema-
tous brain and plasma [85]. In a randomised controlled
trial, 128 patients with ICH were treated either with man-
nitol or sham infusion in their early stage of hospitalisation,
and the result showed no difference in one-month mortality
and secondary outcome [118]. The Cochrane systemic
review, including two trials of mannitol for ICH, did not
find significant differences in mortality and morbidity
between treatment groups and controls [15]. In those
without significant intracranial hypertension or mass effect,
mannitol should not be used but close monitoring should be
applied [136].
For a patient with an increased ICP, elevating the head
to 30 degrees, giving 1.0–1.5 g/kg of 20 % mannitol by a
rapid infusion, and hyperventilating the patient to a pCO2
of 28–32 mmHg are the usual management protocols
[112]. Hypertonic saline is an alternative choice for
decreasing intracranial pressure [91, 139]. Wagner et al.
[167] treated ICH patients with spontaneous lobar and
Fig. 2 Patient with ‘spot sign,’ demonstrating extravasation and haematoma expansion [166]. Reproduced from Wolters Kluwer Health with
permission
Fig. 3 Haematoma heterogeneity and haematoma growth border.
These two patients were admitted to our hospital with the impression
of spontaneous ICH. Patient 1: a CT on admission shows haematoma
heterogeneity with an initial haematoma volume of 15 mL.
b Repeated CT after 32 h shows a haematoma volume of 30 mL.
Patient 2: c CT on admission shows haematoma growth border (black
arrow). d Repeated CT after 10 h shows haematoma expansion with
increased midline shift
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basal ganglia/thalamic bleeding with continuous hyper-
tonic saline infusion within 72 h, and the relative oedema
volume and the occurrence of intracranial pressure crisis
had significantly decreased.
Blood pressure control
The protective effect of anti-hypertensive therapy in ICH
has been broadly explored. A retrospective series of 76
patients by Ohwaki et al. showed that systolic blood
pressure (SBP) of C160 mmHg was significantly asso-
ciated with haematoma enlargement compared to those
of B150 mmHg, and efforts to lower SBP below
150 mmHg may prevent this risk [130]. Also, several
clinical trials have been conducted. The Intensive Blood
Pressure Reduction in Acute Cerebral Hemorrhage Trial
(INTERACT) randomised 404 patients to receive either
standard blood pressure management (SBP \180 mmHg)
or more aggressive blood pressure management (SBP
\140 mmHg); the results showed a decrease in
haematoma expansion by 2.80 mL, with no significant
difference in perihaematomal oedema [8]. The results of
the INTERACT phase 2 trail, performed on 2,839
patients, showed no significant reduction of haematoma
expansion but significant improved functional outcome
in the intensive blood pressure lowering group compared
to the control group [7]. The Antihypertensive Treatment
of Acute Cerebral Hemorrhage (ATACH) study ran-
domised 60 patients to receive intravenous nicardipine
hydrochloride to three systolic blood pressure reduction
goals: 170–199, 140–169, or 110–139 mmHg. The post
hoc analysis results showed that patients with a lower
blood pressure were less likely to have haematoma
expansion, perihaematomal oedema, and a poor 3-month
outcome [137].
Presently, based on the existing incomplete evidence,
AHA/ASA guidelines recommend that for patients with
SBP of [200 mmHg or MAP of [150 mmHg, continuous
intravenous infusion to reduce the BP should be applied,
with BP monitoring every 5 min. For SBP of[180 mmHg
or MAP of [130 mmHg in patients with a likelihood of
ICP elevation, reducing BP while simultaneously main-
taining a cerebral perfusion pressure of C60 mmHg is
recommended. If there is no evidence of elevated ICP, then
a modest reduction of BP (e.g., MAP of 110 mmHg or a
target BP of 160/90 mmHg) with a re-examination every
15 min is recommended [121].
Coagulopathy reversal
Because coagulopathy contributes to the early progression
of haemorrhagic stroke, ultra-early haemostatic therapies
have been introduced to stabilise the condition and reduce
the progressing [109]. For those patients who have been
taking oral anticoagulants, such as warfarin, it is necessary
to withdraw the drug and initiate a rapid reversal therapy,
because it contributes to both a higher incidence of
haematoma expansion [45, 47] and a higher mortality rate
[145]. However, because warfarin may only contribute to
rather than cause a role in the pathogenesis of ICH [146],
discontinuing warfarin therapy with the administration of
vitamin K is not sufficient. PCC [5, 24], rFVIIa [5], or FFP
[60] are often considered [3, 4, 107]. Schlunk et al. [148]
compared rFVIIa and PCC use in experimental warfarin-
associated ICH and showed that they both could reduce the
haematoma enlargement, with no significant difference in
the reduction. A retrospective study showed that PCC was
effective in reducing the fatality of warfarin-associated
ICH [76]. Huttner et al. [77] retrospectively reviewed 55
patients who received PCC alone or in combination with
FFP or vitamin K (n = 31), with FFP alone or in combi-
nation with vitamin K (n = 18), or with vitamin K as a
monotherapy (n = 6), and the results showed that the
incidence and the extent of haematoma growth were lower
in patients receiving PCC compared with FFP and vitamin
K. However, in a prospective research, de Lecin˜ana et al.
sought to detect the effect of anticoagulation reversal
treatment in vitamin K antagonist-associated ICH, and the
results showed that of anticoagulation reversal treat-
ments—PCC with or without vitamin K, vitamin K
monotherapy, or FFP with or without vitamin K—none
were related to reduced mortality or functional outcome
[31].
For anticoagulants, such as dabigatran, rivaroxaban or
lepirudin, the previous antithrombotic therapy could also
be applied, although there is no consensus for the treatment
protocol [3, 95]. Because the role of antiplatelets in ICH
has not been established, there is no recommended therapy
for reversal, whereas the application of desmopressin
acetate was reported by several researchers [3].
Recombinant activated factor VII for ICH has been
explored in many studies. The Factor VII for Acute Intra-
cerebral Hemorrhage phase IIB and phase III trials both
showed that with an increased dose of rFVIIa, the
haematoma growth volume decreased [110, 111]. How-
ever, the phase III trial showed that rFVII neither reduced
mortality nor improved functional outcome [110]. The
Cochrane systemic review, including six clinical trials with
975 patients receiving haemostatic drugs (two with epsi-
lon-aminocaproic acid and 973 with rFVIIa), found no
evidence of a reduction of death or dependence by hae-
mostatic drugs [6]. Tranexamic acid is another hemostatic
agent, and two multicentered clinical trials on tranexamic
acid for ICH are presently recruiting patients [1, 115].
J Neurol (2014) 261:2061–2078 2067
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Blood glucose control
Although both diabetes and hyperglycaemia in non-dia-
betic patients were shown to have a higher early mortality,
there are no agreed criteria of blood glucose control in the
acute phase of ICH [131]. A prospective study by Godoy
et al. [58] showed that insulin application within the first
12 h after ICH onset attenuated the association of hyper-
glycaemia with mortality. Ho et al. [70] selected 12
patients who underwent surgeries for spontaneous ICH and
randomised them to intermittent or intensive continuous
insulin infusion to maintain the blood glucose level
between 4.0 and 8.0 mmol/L; the results showed that the
continuous insulin infusion group had a lower MAP and
ICP postoperatively. A randomised, controlled trial aimed
at detecting whether 24 h of intensive glucose control by
glucose-potassium-insulin infusions could reduce mortality
or improve functional outcome failed to show a positive
result, although the trial mainly focused on patients with
ischemic stroke; the data of patients with ICH were not
individually reported [62].
Presently, the AHA/ASA guidelines recommended that
blood glucose should be maintained within normal range
for patients with acute ICH [122].
Anti-inflammation therapy
Randomised trials have failed to demonstrate the efficacy
of corticosteroids and, therefore, corticosteroid therapy is
not recommended to treat patients with ICH [132, 161].
There are no other reported clinical trials that target the
inflammatory cascade, although in several animal exam-
inations, protease-activated receptor antagonists, iron che-
lators, N-acetylheparin, heme degradation inhibitors and
antioxidants have been used [61, 74, 82].
Surgeries
Whether surgeries are beneficial for the patients with early
haemorrhagic stroke has been controversial for a long time
[42]. A retrospective analysis of Morioka suggested that
surgically treated patients in the early stages of ICH
demonstrated a better outcome [123]. The Surgical Trial in
Intracerebral Hemorrhage (STICH) trial randomised 1,033
patients to receive either early surgery or conservative
treatment, and the results showed no benefit of early sur-
gery in patients with ICH [114]. However, the STICH trial
neither individually explored those who are specifically
thought to be more suitable for surgeries nor the results of
certain types of surgery [112]. A meta-analysis involving
10 trials concluded that surgery added to medical man-
agement reduced the mortality rate and dependence after
ICH [134]. Another meta-analysis that enrolled eight
studies revealed that certain patients might benefit from
surgery: within 8 h of onset, a volume of the haematoma
between 20 and 50 mL, Glasgow Coma Score between 9
and 12, patients’ age range between 50 and 69 years, and
superficial haematomas with no intraventricular haemor-
rhage [63].
The surgical methods include craniotomy, decompres-
sive craniectomy, stereotactic aspiration, endoscopic aspi-
ration, and catheter aspiration aimed at removing the clot
[42, 63]. Certain types of surgeries may decrease the early
progression of ICH. Rabinstein et al. [140] reviewed 26
patients with rapidly worsening symptoms with a signifi-
cant mass effect who received craniotomy, and 22 % of the
patients gained functional independence. Decompressive
craniectomy is often combined with haematoma evacuation
in treating ICH [160]. Fung et al. reviewed 12 patients who
received decompressive craniectomy only, with 15 mat-
ched controls who were treated conservatively; three
patients (25 %) of the treatment group died versus eight of
15 (53 %) of the control group, which shows feasibility for
decompressive craniectomy without evacuation in treating
ICH [53]. Because the clot and thrombin were the primary
predisposing factors of the perihaematomal oedema
development, Mould et al. conducted the Minimally Inva-
sive Surgery and rtPA in ICH evacuation (MISTI) trial to
evaluate the effectiveness of the clot lysis method. Their
trial comprised 81 patients with minimally invasive surgery
combined with recombinant tissue plasminogen activator
administration and 42 patients with standard therapy; the
results showed that both the haematoma volume and peri-
haematomal oedema were lower in the surgical group
[124]. A meta-analysis by Zhou et al. involving 12 high-
quality randomised, controlled trials concluded that mini-
mally invasive surgery, especially stereotactic aspiration,
could significantly reduce the early mortality of patients
with ICH, and those with a superficial haematoma between
25 and 40 mL might most likely benefit from such sur-
geries [183].
For intraventricular extension of ICH, the removal of the
blood clot in animal experiments showed benefits by con-
trolling ICP, improving the level of consciousness and
preventing tissue inflammation [67]. Compared to conser-
vative therapy, extraventricular drainage, especially with
fibrinolytic agents such as rtPA, significantly improved the
case fatality rate and outcome [129]. rtPA may accelerate
the clot lysis [126], but it also has the risk of aggregating
bleeding. Naff et al. [125] tested removing the intraven-
tricular haemorrhage with a catheter-delivered rtPA in the
Clot Lysis: Evaluating Accelerated Resolution of IVH
(CLEAR-IVH) trial; the results showed that the mortality
rate, ventriculitis occurrence and bleeding events were all
significantly lower in the treatment group, without signif-
icant changes in the systemic haematologic status [68].
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Stroke unit
The observational study of Diringer and Edwards [37]
showed that ICH patients admitted to a neuro intensive care
unit is associated with reduced mortality rate, compared to
those admitted to general ICU. Organized stroke care, or
stroke unit, is effective in reducing mortality, institution-
alization, and dependence in treating stroke patients [153],
and it is recommended as a primary care model for stroke
in many guidelines [41, 80, 128]. A recent systemic review
including eight trials also showed that for ICH patients,
stroke unit care was associated with a significant reduction
of death or dependency [94].
Subacute progressing haemorrhagic stroke
Clinical features
Several of the patients with intracerebral haemorrhage
develop late-onset deterioration, which often occurs during
the second and third weeks. Although complications such as
re-bleeding, deep vein thrombosis, and pneumonitis may
occur, the subacute progression of haemorrhagic stroke
should primarily be attributed to the increased mass effect
produced by secondary oedema [11, 124]. As previously
described, perihaematomal oedema has two peaks: in the
fourth or fifth days, or during the second and third week [26,
165, 182]. This special feature of ICH is consistent with the
progression of perihaematomal oedema after the onset of
ICH [26, 79]. Subacute natural progression has not been
reported much, and it is hard to identify in the beginning.
Causes
Delayed perihaematomal oedema
Inaji et al. [79] investigated the chronological changes of
perihaematomal oedema in 14 patients with CT scan and
found that its volume increased rapidly within 3 days after
haemorrhage, subsequently increased slowly until day 14,
and decreased thereafter. Consistently, Venkatasubrama-
nian et al. [165] investigated 27 patients prospectively with
MR imaging and found that oedema volume growth was
fastest in the first 2 days, and continued until 12 ± 3 days.
By 2 weeks, the haemorrhage volume decreased, whereas
oedema and haemorrhage plus oedema volumes signifi-
cantly increased [11, 52]. A retrospective study involving
490 patients revealed that after admission to the hospital,
the perihaematomal oedema increased, whereas the
haematoma volume decreased, and the mass effect almost
doubled between 7 and 11 days, which could cause an
increase in ICP and secondary clinical deterioration [151].
Tension haematoma
A specific ‘tension haematoma’, reported by Chinese
scholars, might also develop in this phase. The patients
often have a history of hypertension. The main features of
tension haematoma are as follows: a sudden increase of
ICP after the initial alleviation during conservative therapy,
with a CT scan showing large regions of low density, i-
sodensity or mixed-density near the initial haemorrhage
[75]. A contrast CT could be used to distinguish perihae-
matomal oedema from tension haematoma. The ring-
enhancement [172] on contrast CT at that time indicated
the formation of tension haematoma, with regions interior
to the ring-enhancement demonstrated tension haematoma,
whereas the regions exterior to the ring-enhancement
demonstrated perihaematomal oedema [105] (Fig. 4).
Mechanisms
Red blood cell lysis and iron toxicity
Different from the initial oedema, the delayed perihae-
matomal oedema is mainly caused by erythrocyte lysis [72,
177]. It has been observed in ICH patients that during the
second week, the perihaematomal oedema increases in size
simultaneously with the lysis of the clot [173]. In several
animal experiments, the intracerebral infusion of packed
erythrocytes to the ICH rats caused oedema 3 days later
[176], whereas the intracerebral infusion of lysed erythro-
cytes caused oedema within 24 h [175, 176], similar to the
infusion of haemoglobin [174]. Furthermore, the upregu-
lation of the primary heme degradation enzyme, heme
oxygenase-1 (HO-1), has been observed in experimental
ICH [169], simultaneously inhibiting HO-1 attenuated the
brain oedema [174]. The infusion of haemoglobin degra-
dation products, such as heme and Fe2?, could also induce
brain oedema, whereas the oedema caused by the haemo-
globin infusion could be attenuated by the infusion of iron
chelator deferoxamine, indicating that iron degraded from
haemoglobin is the primary cytotoxic factor that contrib-
uted to the delayed brain oedema [74].
Granulation tissue formation
Formation of tension haematoma is related to the granu-
lation tissue around the initial haematoma. During the
absorption of a haematoma, granulation tissues form
around it, which can be seen on contrast CT as ring-
enhancement [172]. The granulation tissue is capsule-like
which limits the absorption of haematomas. Subsequently,
the oncotic pressure inside the haematoma increases and
the infiltration of plasma increases the tension inside the
capsule progressively [162]. Additionally, blood may leak
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from the abundant capillaries contained in the granulation
tissue repeatedly. Thus, this severely increased tension
inside the initial haematoma cavity contributes to rapidly




When a sudden deterioration of clinical signs and symp-
toms occur during the conservative treatment process, a
subacute progression of ICH should be suspected. A
repeated CT at this time is necessary to determine whether
there is increased mass effect or re-bleeding. The priority is
to control the ICP, and a more intensive osmotherapy
should be applied. Placement of an ICP monitor is rec-
ommended, especially in patients with a Glasgow Coma
Scale score of less than eight and those with transtentorial
herniation [122]. Several researchers have recommended
an early and continuous infusion of hypertonic saline to
reduce the impending perihaematomal oedema and pro-
gression of mass effect [167]. However, osmotherapy
might not be beneficial for certain patients; therefore,
surgery would be the best recommendation for these
patients.
Surgeries
As previously described, minimally invasive surgery is
more applicable in reducing the perihaematomal oedema
progression [124]. For the patients with tension
haematoma, surgery is the only way to relieve the severely
increased tension inside the haematoma [105]. If the
hyperosmolar therapy was ineffective, a tension haema-
toma should be suspected. Once CT or MRI confirms the
presence of a tension haematoma and markedly increased
the mass effect, surgery is needed immediately to rescue
the patient from rapidly increasing intracranial pressure.
Such patients may benefit from stereotactic aspiration due
to the highly increased tension inside the haematoma cavity
[75, 105] (Fig. 5).
Chronic progressing haemorrhagic stroke: chronic
encapsulated intracerebral haematoma
Clinical features
Chronic encapsulated intracerebral haematoma or chronic
expanding intracerebral haematoma (CEICH) was first
described by Hirsh in 1981 [69]; although it has been
known for a long time, its causes and mechanisms have not
been established. Different from spontaneous ICH, CEICH
is characterised by a slow and gradual onset. The symp-
toms often evolve and appear within weeks or months,
including seizures, progressive neurological deficit, such as
mental disturbance, ataxia, hemianopia or hemiparesis,
symptoms of increased intracranial pressure such as nau-
sea, vomiting, headache, and papilloedema [108, 133, 147].
Neuroimaging strategies help to diagnose CEICH. The
characteristic CT findings are round or similar round lesion
with variable density, with or without calcification [28],
and usually produce significant perilesional oedema and
Fig. 4 A case of subacute progressing stroke. The patient was
admitted to our hospital because of dysphagia, hemiparalysis, and
conscious disturbance. a CT on hospital admission showed left
parietal and frontal intracerebral haemorrhage. After the initial
treatment, the patient regained consciousness. b 10 days after hospital
admission, the patient became lethargic, and repeated CT showed an
increased mass effect and midline shift, with enlargement of the
perihaematomal oedema. Stronger osmotic therapy was applied
immediately and the patient’s consciousness improved. c Repeated
CT at 17 days post hospital admission showed that the initial
haematoma shrank further, the density of the brain oedema decreased,
and the mass effect alleviated modestly. d An enhanced CT at
17 days showed no ring-enhancement, eliminating the tension
haematoma
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mass effect [25, 133, 147, 181]. Therefore, CEICH
resembles an intracranial tumour or brain abscess and was
initially easily misdiagnosed as those two [143, 181].
Characteristic MRI findings include: high-signal lesions
indicating chronic haemorrhage with mixed-signal, which
indicates recent haemorrhage on both T1 and T2 weighed
images; low-signal surroundings on T2 images suggesting
a fibrous encapsulation around the lesion [181]. Digital
subtraction angiography is useful in detecting some of the
underlying causes of CEICH [92, 127].
Causes
For the encapsulated haematoma or CEICH, occult vas-
cular malformations are often the underlying cause. Arte-
riovenous malformations [133], cavernomas [64, 120],
microaneurysms, vascular amyloidosis or atherosclerosis
are the common underlying causes [108, 133, 147]. CEICH
also occurs after radiosurgeries [92] or trauma [25, 181].
Several causes remain unknown [147].
Whether hypertension contributes to the causes of
CEICH is controversial. Most of the cases reported do not
have a history of hypertension [64, 120], whereas several
cases have been reported to be likely caused by hyperten-
sion [102]. Liquified chronic intracerebral haematomas is
often secondary to hypertension [179] (Table 2).
Mechanisms
The mechanism of the progression of CEICH has not been
established, and it is hard to predict whether CEICH will
affect certain patients. On histological examination,
CEICH consists of central haematoma and peripheral thick
Fig. 5 Management of
subacute progressing stroke
Table 2 Causes of CEICH
Etiology References
Hypertension Yashon et al. [179]
Lin et al. [102]
Arteriovenous malformation Hirsh et al. [69]
Pozzati et al. [133]
Sakaida et al. [147]
Cavernoma Masuzawa et al. [108]
Monma et al. [120]
Greiner-Perth et al. [64]
Radiosurgery Kurita et al. [92]
Lee et al. [96]
Nakamizo et al. [127]
Foroughi et al. [49]
Trauma Yuguang et al. [181]
Cakir et al. [25]
Unknown Pozzati et al. [133]
Fiumara et al. [44]
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capsule. The haematoma often contains abundant blood
clots at varied stages of development, hemosiderin-laden
macrophages, cholesterol clefts, calcifications, fibrous tis-
sue, and can present with or without arteriovenous mal-
formations [102]. The capsule is composed of a thick outer
membrane of dense collagen fibres and an inner thin
granulation tissue rich in capillary [120, 127]. Researchers
believed that some of the initial bleeding could stimulate a
reactive response in the peripheral cerebral tissue and
promote arachnoid fibroblast or collagen tissue to prolif-
erate, forming the initial capsule membrane [44]; the sub-
sequent repetitive bleeding or exudation produces
granulation tissue and promotes the fibroblastic reaction to
develop into a fibrous capsule [102, 181]. The blood ele-
ments leak into the cavity, causing the haematoma to
expand [102].
In those patients without obvious vascular malformation
in their histological examination, occult cerebrovascular
malformations might account for the initial haemorrhage,
which might be destroyed in the haemorrhagic episode
[102, 143]. Pozzati et al. believes that the ‘self-destroying’
nature of the cerebral malformation primarily contributes
to the formation of CEICH [133].
As for the radiosurgery, repetitive minor bleeding within
the radionecrotic brain tissue most likely may initiate the
formation of CEICH [49, 92, 96]. Nakamizo et al. [127]
believes that radiosurgery could impose hypoxic stress on
the surrounding brain tissue and induce a transcription of
vascular endothelial growth factor, which could contribute
to the abnormal angiogenesis and vascular leakage that
expand the haematoma (Fig. 6).
Managements of CEICH
Although spontaneous regression has been reported [64],
most researchers recommend surgery for treating CEICH
[127]. Because the recurrent bleeding of the capsule and
abnormal vessels are the primary cause of the progression
of CEICH, the capsule and hidden vessel malformation
should also be evacuated as much as possible, as much as
the haematoma itself, to avoid relapse and re-bleeding
[181]. The entire lesion and the adjacent brain tissue should
be carefully examined to rule out potential vascular mal-
formation [64]. The prognosis of CEICH after surgery is
usually good; however, patients could die from recurrent
bleeding [133].
Conclusions and future directions
In conclusion, we have proposed the concept of progress-
ing haemorrhagic stroke, and we explored several aspects
of its categories, causes, mechanisms and management.
Despite tremendous efforts in this field, early deterioration
and death are serious problems in patients with spontane-
ous intracerebral haemorrhage. Although some work has
been conducted or is being performed to test the effec-
tiveness of possible treatments, additional exploration of
Fig. 6 Mechanisms of CEICH
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the mechanisms underlying the early deterioration is
required. Furthermore, because of the special second
oedema peak in ICH, subacute haemorrhagic stroke is
specific in haemorrhagic stroke. However, subacute
haemorrhagic stroke has rarely been reported or explored,
although it is an important clinical entity that deserves
concern. The causes and mechanisms are not very well
understood, and the standard treatments need to be estab-
lished. Chronic encapsulated intracerebral haemorrhage
has gained increasing attention not only because of the
more frequent recognition but also because of the preva-
lence of radiosurgery application in treating neurological
diseases. More effective ways to predict and prevent the
occurrence of CEICH are warranted.
Search strategy and selection criteria
We searched PubMed, China National Knowledge Infra-
structure (CNKI) and the Cochrane Library. We also
searched the reference lists of retrieved articles, and we
cross-referenced. Search terms included ‘‘progressing
stroke’’, ‘‘progressive stroke’’, ‘‘stroke-in-evolution’’,
‘‘h(a)emorrhagic stroke’’, ‘‘cerebral h(a)emorrhage’’,
‘‘intracerebral h(a)emorrhage’’, ‘‘spontaneous intracerebral
h(a)emorrhage’’, ‘‘early neurological deterioration’’, ‘‘sec-
ondary neurological deterioration’’, ‘‘chronic encapsulated
intracerebral h(a)emorrhage’’, ‘‘h(a)ematoma expansion’’,
‘‘perih(a)ematomal (o)edema’’, ‘‘intraventricular h(a)em-
orrhage’’, ‘‘tension h(a)ematoma’’, ‘‘inflammation’’,
‘‘treatment’’, and ‘‘management’’. The search included
both human and animal studies. Papers published in both
English and Chinese from 1971 to 2013 were reviewed.
Articles were selected on the basis of relevance to the
topics covered in the Review. Where issues are contro-
versial, evidence on both sides of the issue is given.
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